Data availability :
The data that support the findings of this study are available from the corresponding author (M.Y) upon reasonable request.
References:
  1. Quinn M, Babb P. Patterns and trends in prostate cancer. Incidence, survival, prevalence and mortality. Part 1: international comparisons. B JU Int. 2002;90(2):162-173
  2. Ferro MA, Barnes I, Roberts JBM, Smith PJB . Tumour markers in prostatic carcinoma: a comparison of prostate-specific antigen with acid phosphatase. Br J Urol 1987;60:69-73
  3. Braun K, Sjoberg DD, Vickers AJ, et al . A fourkallikrein panel predicts high grade cancer on biopsy: independent validation in a community cohort. E. Urol. 2016;69:505-511
  4. Zappala S, Scardino P, Okrongly D, et al . Clinical performance of the 4K®score to test to predict high-grade prostate cancer at biopsy:A meta-analysis of US and European clinical validation study results.Rev Urol. 2017; 19(3):149-155
  5. Punnen S, Pavan N, Parekh DJ . Finding the wolf in sheep’s clothing: the 4K®score Test is a novel blood test that can acuurately identify the risk of aggressive prostate cancer. Rev Urol. 2015;17:3-13
  6. Stattin P, Vickers AJ, Sjoberg DD et al. Eur Urol. 2015 Aug;68(2):207-13.
  7. Voigt JD, Dong Y, Linder V, Zappala S . Use of the 4K®score test to predict the risk of aggressive prostate cancer prior to prostate biopsy: overall cost savings and improved quality of care to the US healthcare system. Rev Urol. 2017;19:1-10
  8. Kutikov A, Weinberg D, Edelman M, et al . A war on two fronts: cancer care in the time of COVID-19. Ann Intern Med 2020; Mar 27 : M20-1133
  9. Kaufman H, Chen Z, Niles J, Fesko Y . Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Netw. Open. 2020;3(8). E
  10. Maringe C, Spicer J, Morris M, et al . The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8): 1023-1034
  11. Center M, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61(6). 1079-1092
  12. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin.  2014;64:9-29
  13. Dall’Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol.  2012;62:976–983
  14. Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol.  2013;23:331–336
  15. Jordan R, Adab P, Cheng KK . COVID-19: risk factors for severe disease and death. BMJ. 2020
  16. Vrdoljak E, Sullivan R, Lawlwe M . Cancer and corona virus disease 2019; how do we manage cancer optimally through a public health crisis? Eur J Cancer. 2020;132:98-99
  17. Mazza C, Ricci E, Siondi S . A nationwide survey of psychological distress among Italian people during the COVID-19 pandemic: immediate psychological responses and associated factors. Int J Environ Res Public Health. 2020;17(9):3165
  18. Savin Z, Dekalo S, Marom R, et al . The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findings- implications for the COVID-19 era. Urol Oncol. 2021;39(1). 73.e1-73e8